

... How Predfoam helps solve the problems currently associated with local therapy:

- *DISPOSABLE APPLICATORS*
  — Clean and simple to use
- *UNIQUE METERED DOSE AEROSOL*
  — Ensures dosage uniformity
- *PREDNISOLONE METASULPHOBENZOATE*
  — High local tissue levels[1] — 10-100 times those produced by enema formulations of prednisolone[2]

PREDFOAM®

PREDNISOLONE METASULPHOBENZOATE

Prescribing Information

Presentation: A white mucoadherent aerosol foam containing prednisolone metasulphobenzoate sodium equivalent to 20mg prednisolone per metered dose.

Uses: Treatment of proctitis and ulcerative colitis.

Dosage and Administration: One metered dose inserted rectally once or twice daily for two weeks, extending treatment for a further two weeks when a good response is obtained.

Contra-indications, warnings, etc:
Contra-indications: Local conditions where infection might be masked or healing impaired eg. peritonitis, fistulae, intestinal obstruction, perforation of the bowel.

Side effects: The consequences of systemic absorption should be considered with extensive use over prolonged periods. As with all rectal corticosteroids, prolonged continuous use is undesirable.

There is inadequate evidence of safety in human pregnancy. Topical administration of corticosteroids to pregnant animals can cause abnormalities of foetal development including cleft palate and intra-uterine growth retardation. There may therefore be a very small risk of such effects in the human foetus. Overdosage by this route is unlikely.

Legal Category : POM
PL 0108/0101

Pack and basic NHS price : Box containing 1 fourteen-dose canister, 14 disposable nozzles and 14 plastic bags £7.00

* *Registered Trade Mark*

*References: (1) McIntyre, PB. et al. (1985) GUT **26** 822-824*
(2) Rodrigues, C. et al. (1987) Lancet, June 27th, 1497.

Full information is available on request

PHARMAX LIMITED
Bourne Road, Bexley, Kent. DA5 1NX
Telephone 0322 91321

NEW

ANNOUNCING THE FIRST SPECIFICALLY DEVELOPED

THE IMPORTANCE OF NIGHT-TIME COVER

Leading gastroenterologists say that the inhibition of nocturnal acid is the key to successful peptic ulcer therapy.[1,2]
During the day, normal gastric acid is required for natural digestion and as protection against unwanted ingested bacteria. 'PEPCID' PM, the first H_2-receptor antagonist specifically developed for night-time use, inhibits acid production when it's not needed.
'PEPCID' PM, when administered at night, effectively controls nocturnal acidity in most duodenal ulcer patients, providing rapid healing and swift relief of pain. 'PEPCID' PM has been shown to achieve a 90.5% healing of duodenal ulcers within four weeks[4] and up to 81% of gastric ulcers within eight weeks.[5]
That's 'PEPCID' PM, a simple, once-nightly 40 mg tablet, supplied in a convenient 28-day calendar pack to help maximise compliance.



ABRIDGED PRODUCT INFORMATION ▼

Full prescribing information is available and should be consulted before prescribing.
INDICATIONS Duodenal ulcer; prevention of relapses of duodenal ulceration; benign gastric ulcer; hypersecretory conditions such as Zollinger-Ellison syndrome.
DOSAGE In duodenal and benign gastric ulcer, 40 mg at night for four to eight weeks.
For prevention of duodenal ulcer recurrence, 20 mg at night.
Initiate antisecretory therapy of Zollinger-Ellison syndrome with 20 mg every six hours and adjust to individual response. Maximum 480 mg daily.
CONTRA-INDICATION Hypersensitivity.
PRECAUTIONS Exclude any likelihood of gastric carcinoma before using 'PEPCID' PM.
Consider reducing the daily dose if creatinine clearance falls to or below 30 ml/min.
'PEPCID' PM is not recommended in pregnancy, nursing mothers or children.
SIDE EFFECTS Rarely, headache, dizziness, constipation, diarrhoea. Less frequently, dry mouth, nausea, vomiting, rash, abdominal discomfort, anorexia, fatigue.
BASIC NHS COST 20 mg tablets, £14.00 for 28-day calendar pack and £25.00 for bottles of 50.
40 mg tablets, £26.60 for 28-day calendar pack and £47.50 for bottles of 50.
PRODUCT LICENCE NUMBERS: 20 mg tablets, 0025/0215; 40 mg tablets, 0025/0216.
▼ Special reporting to the CSM required.
Issued September 1987.
TM denotes trademark

References
1. Gledhill, T., *et al., Gut,* 1983, **24**, 904.
2. Ireland, A., *et al., Lancet,* 1984, ii 274.
3. Bauerfeind, P., *et al., Gastroenterology,* 1986, **90**(5), 1340.
4. Mann, S. G., Cottrell, J., *Ital. J. Gastroenterol.,* 1987, **19** (Suppl. 3), 68.
5. Data on file, Merck Sharp & Dohme Research Laboratories.

Thomas Morson Pharmaceuticals
Hertford Road, Hoddesdon, Hertfordshire
Division of Merck Sharp & Dohme Limited

8-88 PCD.87.GB.1231.J.

H_2-RECEPTOR ANTAGONIST FOR ONCE-NIGHTLY USE

NIGHT-TIME COVER FROM A SINGLE DOSE[3]



Efficacy of 'PEPCID' PM and ranitidine after intake at 6 p.m.
Median pH values for evening, night and day.[3]

n=7

Adapted from Reference 3.

PEPCID™ PM

40mg (famotidine)

One at night can make their day

Before she started Colifoam therapy, sailing was just a dream.

Colifoam gives your patients much greater personal freedom in their daily lives.[1,2]

So, while steroid enemas may equal Colifoam's effectiveness clinically,[1,2] when it comes to patient preference there's no comparison.

Colifoam is also unique among foam treatments with an unrivalled 12 years of proven efficacy and safety in clinical practice. It's a success record that makes Colifoam, more than any other, a prescription of confidence.

The proven choice in distal inflammatory bowel disease

1. Ruddell WSJ et al. Gut 1980; 21: 885-889 2. Somerville KW et al. British Medical Journal 1985; 291: 866

PRESCRIBING INFORMATION: Presentation: White odourless aerosol containing hydrocortisone acetate PhEur 10%. Uses: Ulcerative colitis, proctosigmoiditis and granular proctitis. Dosage and administration: One applicatorful inserted into the rectum once or twice daily for two or three weeks and every second day thereafter. Shake can vigorously before use (illustrated instructions are enclosed with pack). Contra-indications, warnings etc.: Local contra-indications to the use of intrarectal steroids include obstruction, abscess, perforation, peritonitis, fresh intestinal anastomoses and extensive fistulae. General precautions common to all corticosteroid therapy should be observed during treatment with Colifoam. Treatment should be administered with caution in patients with severe ulcerative disease because of their predisposition to perforation of the bowel wall. Safety during pregnancy has not been fully established. Pharmaceutical precautions: Pressurized container. Protect from sunlight and do not expose to temperatures above 50°C. Do not pierce or burn even after use. Do not refrigerate. Keep out of reach of children. For external use only. Legal category: POM. Package Quantity & Basic NHS cost: 25g canister plus applicator, £7.25. Further Information: One applicatorful of Colifoam provides a dose of approximately 125mg of hydrocortisone acetate, similar to that used in a retention enema, for the treatment of ulcerative colitis, sigmoiditis and proctitis. Product Licence No.: 0036/0021. Further information is available on request.
Strafford-Miller Ltd., Professional Relations Division, Hatfield, Herts. AL10 0NZ.



ASACOL delivers 5-aminosalicylic acid directly to the colon without sulphapyridine (the agent in sulphasalazine that can cause distressing side effects).[2]

A patented acrylic coating on **ASACOL** makes it site selective. **ASACOL** remains intact until it reaches the terminal ileum or colon, where pH rises above 7 and dissolves the coating, releasing the 5-ASA.[2,3]

Each **ASACOL** tablet provides twice as much 5-ASA (400 mg) as each tablet of sulphasalazine (200 mg), which allows patients to take fewer tablets daily.

Clinical studies have shown that **ASACOL** offers efficacy comparable to that of sulphasalazine in maintaining the remission of ulcerative colitis.[4]

ASACOL

Direct Delivery to the Colon

ABBREVIATED PRESCRIBING INFORMATION

PRESENTATION

Red tablets containing 400 mg of mesalazine (5-aminosalicylic acid) coated for release in the terminal ileum and colon.

USES

For the maintenance of remission of ulcerative colitis in patients who cannot tolerate sulphasalazine.

DOSAGE AND ADMINISTRATION

Adults: 3 to 6 tablets daily in divided doses.
There is no dose recommendation for children.

CONTRA-INDICATIONS, WARNINGS, ETC.

Contra-indications

Contra-indications: a history of sensitivity to salicylates. Children under 2 years of age.

Precautions

Renal disorder. Mesalazine is excreted rapidly by the kidney mainly as its metabolite, N-acetyl 5-aminosalicylic acid. In rats large doses of mesalazine injected intravenously produce tubular and glomerular toxicity. Although no renal toxicity has been reported in patients taking 'Asacol', it is not recommended in patients with renal impairment and caution should be exercised in patients with a raised blood urea or proteinuria.
Asacol should not be given with lactulose or similar preparations which lower stool pH and may prevent release of mesalazine.

Use during pregnancy

Use of 'Asacol' during pregnancy should be with caution, and only if, in the opinion of the physician, the potential benefits of treatment are generally greater than the possible hazards.

Adverse Reactions

Adverse reactions occur in a small proportion of patients who previously could not tolerate sulphasalazine. The side-effects are predominantly gastrointestinal (nausea, diarrhoea and abdominal pain) and headache. 'Asacol' may be associated with the exacerbation of the symptoms of colitis in those patients who have previously had such problems with sulphasalazine.

Other side effects observed with sulphasalazine such as depression of bone marrow and of sperm count and function, have not been reported with 'Asacol'.

LEGAL CATEGORY: POM. **PL:** 0424/0032.

Daily treatment cost: 66p-£1.31

Licence Holder:
Tillotts Laboratories, Henlow Trading Estate, Henlow, Bedfordshire SG16 6DS.

Supplier:
Smith Kline & French Laboratories Limited
Welwyn Garden City, Hertfordshire AL7 1EY

U.K. Patent No. 8322387 7.4.87

REFERENCES:

1. Dew M.J. Harries A.D. Evans B.K. et al. Treatment of ulcerative colitis with oral 5-aminosalicylic acid in patients unable to take sulphasalazine. *Lancet*, 1983; ii:801.
2. Dew M.J. Hughes P.J. Lee M.G. et al. An oral preparation to release drugs in the human colon. *Br. J. Clin. Pharmacol.*, 1982; 14:405-408.
3. Dew M.J. Ryder R.E.J. Evans N. et al. Colonic release of 5-aminosalicylic acid from an oral preparation in active ulcerative colitis. *Br. J. Clin. Pharmacol.*, 1983; 16:185-187.
4. Dew M.J. Hughes P.J. Harries A.D. et al. Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid. *Br. Med. J.*, 1982; 285:1012.
5. Dew M.J. Harries A.D. Evans N. et al. Maintenance of remission in ulcerative colitis with 5-aminosalicylic acid in high doses by mouth. *Br. Med. J.*, 1983; 287 23-24.

***Mesalazine is the British Approved name for 5-aminosalicylic acid.**

SK&F Smith Kline & French Laboratories Limited
A SMITHKLINE BECKMAN COMPANY
Welwyn Garden City, Hertfordshire AL7 1EY

The KeyMed Auto-Disinfector...



DESIGNED FOR ALL
OLYMPUS
IMMERSIBLE FIBERSCOPES

...Makes Endoscope Disinfection Easy

Manual irrigation and disinfection of fiberscopes is a tedious and time consuming task, set against the background of increasing risks of cross-infection. Automated processing ensures decontamination to a consistently high level, releasing valuable nursing time for patient care.



An eye level control panel with touch sensitive switches to operate all functions.

Designed to process all Olympus OES immersible fiberscopes, providing the benefits of total immersion and all channel irrigation*.



Self-contained, mobile and requiring no plumbing — easily removable lids allow simple access to the fluid containers.

Once you have used the Auto-Disinfector, we believe you will never look back.

For further information or to arrange a practical evaluation of the KeyMed Auto-Disinfector in your own unit, contact our Medical Customer Liaison Department.

* excluding raiser bridge channel on JF series, GIF-K10 and GIF-D10.

KeyMed

Specialised Services to Medicine

KeyMed (Medical & Industrial Equipment) Ltd.
KeyMed House, Stock Road, Southend-on-Sea, Essex SS2 5QH.
Telex: 995283, Facsimile: (0702) 65677, Telephone: (0702) 616333 (24 lines).

REGISTERED MANUFACTURER

Medical Equipment

Scotland: KeyMed, Peel House, Ladywell East, Livingston EH54 6AH. Telephone: (0506) 416655

Ireland: KeyMed Ireland Ltd., KeyMed House, Lord Edward Court, Bride Street, Dublin 8. Telephone: 774855

USA: KeyMed Inc., 400 Airport Executive Park, Spring Valley, New York 10977. Telephone: (914) 425-3100

TABLETS

New Evoxin

domperidone

activates the static stomach

for relief of nausea and vomiting

A move in the right direction

SRL

Evoxin is a trade mark. Full information available from Sterling Research Laboratories, Onslow Street, Guildford, Surrey GU1 4YS.

(SRL0521)587

Coated VICRYL*
(polyglactin 910)



Surgeons are turning to Coated VICRYL.

Coated VICRYL*
(polyglactin 910) braided sutures

ETHICON
a Johnson & Johnson company

ETHICON Ltd., P.O. Box 408, Bankhead Avenue,
Edinburgh EH11 4HE, United Kingdom.

TECHNICAL DATA

COATED VICRYL* (POLYGLACTIN 910) STERILISED BRAIDED SYNTHETIC ABSORBABLE SUTURE

Presentation The basic VICRYL (Polyglactin 910) Suture is prepared from a copolymer of glycolide and lactide. The substances are derived respectively from glycolic and lactic acids. The empirical formula of the copolymer is $(C_2H_2O_2)m(C_3H_4O_2)n$.

Coated VICRYL (Polyglactin 910) Sutures are obtained by coating the braided suture material with a mixture composed of a copolymer of glycolide and lactide and an equal amount of calcium stearate. This coating does not affect the biological properties of the suture.

Coated VICRYL (Polyglactin 910) Sutures are coloured by adding D & C Violet No 2 during polymerisation of the lactide and glycolide. Sutures may also be manufactured in the undyed form.

These sutures are relatively inert, nonantigenic, nonpyrogenic and elicit only a mild tissue reaction during absorption.

Action: Two important characteristics describe the in vivo behaviour of absorbable sutures. The first of these is tensile strength retention and the second, absorption rate or loss of mass.

Subcutaneous tissue implantation studies of Coated VICRYL Suture in rats show at two weeks post-implantation approximately 55% of its original tensile strength remains, while at three weeks approximately 20% of its original strength is retained.

Intramuscular implantation studies in rats show that the absorption of these sutures is minimal until about the 40th post-implantation day. Absorption is essentially complete between the 60th and 90th days.

Uses Coated VICRYL synthetic absorbable sutures are intended for use where an absorbable suture or ligature is indicated.

Dosage and Administration
By implantation.

Contra-indications, Warnings, etc.
These sutures, being absorbable, should not be used where extended approximation of tissues under stress is required.

Sutures placed in skin and conjunctiva may cause localised irritation if left in place for longer than 7 days and should be removed as indicated.

At the discretion of the surgeon, appropriate non-absorbable sutures may be used to provide additional wound support when Coated VICRYL sutures are used in ophthalmic procedures.

The safety and effectiveness of Coated VICRYL (Polyglactin 910) Sutures in neural tissue and in cardiovascular tissue have not been established.

Pharmaceutical Precautions
Do not re-sterilise.

Legal Category.
Not applicable.

Package Quantities Various lengths of material packaged in sealed aluminium foil sachets. This primary pack is contained in a peel-apart secondary pack. The unit of sale is 12 packs contained in a film wrapped drawer style carton.

Further Information No suture related adverse reactions were reported during clinical trials, although a number of minor reactions were classified as being of unknown cause.

Product Licence No 0508/0009
Br. Pat. No. 1583390

Date of Preparation of Data Sheet April 1981.
Revised 11/1987.

ETHICON LTD.
PO BOX 408, BANKHEAD AVE
EDINBURGH EH11 4HE

*Trademark

Coated VICRYL*
(polyglactin 910)



More Surgeons are turning to Coated VICRYL.

ETHICON
a Johnson & Johnson company

ETHICON Ltd., P.O. Box 408, Bankhead Avenue,
Edinburgh EH11 4HE, United Kingdom.

Rapid relief for patients gripped by IBS

Colofac rapidly relieves the symptoms of Irritable Bowel Syndrome by a direct action on colonic smooth muscle.

Colofac eliminates spasm without the anti-cholinergic side effects that can prove troublesome to the patient.

colofac®

mebeverine

loosens the grip of IBS

Prescribing Information

Presentation: White, sugar-coated tablets each containing 135mg mebeverine hydrochloride. Available in packs of 100. Basic NHS price £8.35. Yellow, banana-flavoured sugar-free suspension containing mebeverine pamoate equivalent to 50mg mebeverine hydrochloride per 5ml. Available in bottles of 300ml: Basic NHS price £3.50. **Indications:** 1. Irritable bowel syndrome. 2. Gastrointestinal spasm secondary to organic diseases. **Dosage and Administration:** Tablets: Adults and children ten years and over: One tablet three times a day, preferably 20 minutes before meals. Suspension: Adults and children ten years and over: 15ml (150mg) three times a day, preferably 20 minutes before meals. **Contra-indications, warnings, etc:** Animal experiments have failed to show any teratogenic effects. However, the usual precautions concerning the administration of any drug during pregnancy should be observed. **Product Licence Number:** *Tablets:* 0512/0044: *Suspension:* 0512/0061. Further information is available on request to the Company.

duphar Duphar Laboratories Limited, Gaters Hill, West End, Southampton, SO3 3JD. Telephone: 0703 472281

C/Hosp Ad/1/88

Coated VICRYL*
(polyglactin 910)



More and more Surgeons are turning to Coated VICRYL.

Coated VICRYL*
(polyglactin 910) braided sutures

ETHICON
a Johnson & Johnson company

ETHICON Ltd., P.O. Box 408, Bankhead Avenue,
Edinburgh EH11 4HL, United Kingdom



Lets ulcers heal by night and the stomach work by day

A single evening dose of Axid suppresses acid production only during the night[1] when mucosal damage may occur.

Because of its short half-life, Axid then produces minimal suppression of daytime gastric acid.

Axid produces effective ulcer healing[2-4] whilst allowing the stomach to work virtually normally during the day.

NEW

AXID 300mg

NIZATIDINE

ONCE NIGHTLY H_2 ANTAGONIST

▼ **ABBREVIATED PRESCRIBING INFORMATION. Presentation:** Capsules containing 150mg or 300mg nizatidine INN. **Uses:** For the treatment of duodenal and benign gastric ulcer, and prevention of duodenal ulcer recurrence. **Dosage and Administration:** (For full information, see data sheet). Axid is administered orally. *Adults:* For duodenal and benign gastric ulcer, the recommended daily dose is 300mg in the evening for 4 or, if necessary, 8 weeks. For prevention of duodenal ulcer recurrence, the recommended daily dose is 150mg in the evening. *The elderly:* Normally dosage modification is not required except in patients who have moderate to severe renal impairment. *Children:* Not recommended. *Patients with impaired renal function:* Moderate renal impairment (creatinine clearance less than 50ml/min), the dose should be reduced by 50% to 150mg in the evening. Severe renal impairment (creatinine clearance less than 20ml/min), the dose should be reduced by 75%, to 150mg on alternate days. Prevention of duodenal ulcer recurrence in moderate renal impairment (creatinine clearance less than 50ml/min), the dose may be reduced to 150mg on alternate days. Severe renal impairment (creatinine clearance less than 20ml/min), the dose may be reduced to 150mg every third day. **Contra-indication:** Known hypersensitivity to H_2-receptor antagonists. **Warnings:** *Usage in pregnancy:* The safety of nizatidine for use during pregnancy has not been established. *Usage in lactation:* Administer to nursing mothers only if considered absolutely necessary. *Drug interactions:* No interaction has been observed between nizatidine and aminophylline, theophylline, chlordiazepoxide, diazepam, metoprolol, warfarin or lorazepam. Nizatidine does not inhibit the hepatic cytochrome P450-linked drug metabolising enzyme system. **Precautions:** Patients with impaired liver or kidney function should be treated with caution (see data sheet). **Side-effects:** Possible side-effects include headache, asthenia, chest pain, myalgia, abnormal dreams, somnolence, rhinitis, pharyngitis, cough, pruritus, sweating and reversible, asymptomatic elevations of transaminases. *Overdosage:* There is no experience of overdose in humans. Tested at very high doses in animals, nizatidine has been shown to be relatively non-toxic. *Treatment:* Symptomatic and supportive therapy is recommended. Activated charcoal may reduce nizatidine absorption and haemodialysis may remove absorbed nizatidine. **Legal Category:** POM **Product Licence Numbers:** Capsules 150mg 0006/0230. Capsules 300mg 0006/0231. **Basic NHS Cost:** Per 28 day calendar pack – 150mg capsules £11.52; 300mg capsules £23.04. **Date of Preparation:** August 1987. **Full prescribing information is available from:** Eli Lilly & Company Limited, Dextra Court, Chapel Hill, Basingstoke, Hampshire RG21 2SY. Telephone: (0256) 473241.



References: 1. Dammann HG *et al,* Scand J Gastroenterol 1987; 22: 56. 2. Simon B *et al,* Ibid 61. 3. Naccaratto R *et al,* Ibid 71. 4. Cerulli MA *et al,* Ibid 79. 'AXID' is a Lilly trademark.

Lilly

AX48 Dec 87

Olympus Endoscopy System

THE GOLD



– an evolution in endoscopy

STANDARD

The evolution of the Olympus Endoscopy System (OES) 10 series has resulted in a new range — OES-20 — destined to become the 'Gold Standard' in endoscopy.

OES-20 is the culmination of a four year development programme, resulting in instruments which represent a significant advance in fiberscope technology.

High resolution optics, lighter in weight, improved durability, outstanding handling and insertion characteristics are just some of the exciting features offered by the unique OES-20 range of fiberscopes.

The Olympus Endoscopy System — OES-20.





KeyMed

Specialised Services to Medicine

KeyMed (Medical & Industrial Equipment) Ltd.
KeyMed House, Stock Road, Southend-on-Sea, Essex SS2 5QH.
Telex: 995283, Facsimile: (0702) 65677, Telephone: (0702) 616333 (24 lines).

Scotland: KeyMed, Peel House, Ladywell East, Livingston EH54 6AH. Telephone: (0506) 416655

Ireland: KeyMed Ireland Ltd., KeyMed House, Lord Edward Court, Bride Street, Dublin 8. Telephone: 774855

USA: KeyMed Inc., 400 Airport Executive Park, Spring Valley, New York 10977. Telephone: (914) 425-3100

The Gold Standard – Seeing is believing

Extend the range...

of pancreatic enzyme therapy
with the five flexible forms of

PANCREX®

(pancreatin)

Only the PANCREX range provides:

Powder



Capsules

Tablets

Forte Tablets

- **More dosing options for more types and ages of patient**
- **Low daily cost for long-term therapy**

ABRIDGED PRODUCT INFORMATION
Full prescribing information is available and should be consulted before prescribing.

Indications: Fibrocystic disease of the pancreas (cystic fibrosis), chronic pancreatitis and pancreatic steatorrhoea following pancreatectomy. May also be indicated following gastrectomy as an aid to digestion.

Minimum activity in BP Units:

PREPARATION	PROTEASE	LIPASE	AMYLASE
PANCREX V POWDER	1400/g	25,000/g	30,000/g
PANCREX GRANULES	300/g	5,000/g	4,000/g
PANCREX V CAPSULES	430	8,000	9,000
PANCREX V CAPSULES '125'	160	2,950	3,300
PANCREX V TABLETS	110	1,900	1,700
PANCREX V FORTE TABLETS	330	5,600	5,000

PABYRN

Dosage:
PANCREX V POWDER: 1/2-2g swallowed dry or mixed with water or milk, 4 times daily with meals.
PANCREX GRANULES: 5-10g swallowed dry or mixed with water or milk, 4 times daily before meals.
PANCREX V CAPSULES: Infants – contents of 1-2 capsules mixed with feeds. Older children/adults – 2-6 capsules, 4 times daily with meals.
PANCREX V CAPSULES '125': Neonates 1-2 capsules with feeds
PANCREX V TABLETS: 5-15 tablets, 4 times daily before meals
PANCREX V FORTE TABLETS: 6-10 tablets, 4 times daily before meals.

Main Contra-indications/Warnings:
If Pancrex V is mixed with feeds or liquids, the mixture should be consumed within one hour.

In the case of newborn infants high dosage of Pancrex V may result in irritation around the mouth and anus. Barrier creams will prevent such local irritations.

Rare cases of hyperuricosuria have been reported after taking extremely high doses of Pancreatin.

Basic NHS Cost: Pancrex V Powder 100g £6.53, 250g £13.90. Pancrex V Capsules 100 £3.71, 500 £14.37. Pancrex V Capsules '125' 500 £10.89. Pancrex Granules 100g £4.79, 500g £19.16. Pancrex V Tablets 100 £1.79, 500 £4.79. Pancrex V Forte Tablets 100 £3.23, 500 £12.46.

Product Licence Numbers: Pancrex V Powder 0051/5004, Pancrex V Capsules 0051/5043, Pancrex V Capsules '125' 0051/5104, Pancrex Granules 0051/5003, Pancrex V Tablets 0051/5002, Pancrex V Forte Tablets 0051/5000.

Paines & Byrne Limited
Bilton Road, Greenford, Middlesex UB6 7HG

(pancreatin)

NEW

For the relief of symptoms of

DUMPING SYNDROME

"The favourable effect of the addition of guar gum to the meals of patients suffering from the dumping syndrome is based on the normalization (i.e. slowing down) of the passage of food from the stomach to the duodenum and jejenum, and hence the slowing down of the absorption of nutrients, especially monosaccharides, and the prevention of a rapid postprandial increase in intraluminal osmolarity in the duodenum[6]."

- ★ **slows gastric emptying[1–3]**
- ★ **binds bile acid[8]**
- ★ **reduces hyperglycaemia and hyperinsulinaemia[4–5]**
- ★ **helps improve patient comfort, food tolerance and nutritional status[6–7]**

Guarem®

Guar 5g

References 1 Jenkins et al **Br.Med.J.** 1978. 1. 1392 2 Blackburn et al **Clin.Sc.** 1984. **66,** 329 3 Leeds et al **Lancet** 1981. 1. 1075 4 Jenkins **Proc.Soc.Exp.Biol.** 1985. **180,** 422 5 Fuessl et al **Pract.Diab.** 1986. **3,** 258 6 Harju & Larmi **J.Parent.Ent.Nutr.** 1983. **7,** 470 7 Harju & Makela **Amer.J.Gastroent.** 1984. **79,** 861. 8 Hanson et al **Hepato-Gastroent.** 1983. **30,** 161

Clinical Information

Action. Guar gum which is derived from natural sources is a high molecular weight polysaccharide, galactomannan. In solution it (i) increases gastric transit time and (ii) slows the rate of absorption of other carbohydrates leading to a reduction in post prandial hyperglycaemia and insulin secretion. Guar gum is not absorbed and remains chemically unchanged until it reaches the colon where it is broken down before excretion. **Indication.** The relief of the symptoms of the 'dumping syndrome'. **Dosage & Administration.** Adults One 5g sachet to be taken with each main meal. The contents of a sachet are preferably sprinkled evenly over a meal on the plate or stirred into suitable foods (e.g. tomato juice, yoghurt, muesli, etc), in which case the food should be accompanied by a drink of 150ml (⅓ tumbler). **Contra-Indications, Warnings, etc.** To avoid any risk of oesophageal obstruction or rupture, this product should not be given to patients with a history of oesophageal disease or difficulty in swallowing. While Guarem may be expected to reduce malabsorption, usual monitoring of nutritional status should be continued. Guarem should not be ingested as dry granules. **Side-Effects.** Gastro-intestinal symptoms (flatulence, diarrhoea) are quite common at the commencement of treatment. These can be reduced or avoided by initiating treatment gradually, in accordance with advice on the pack. **Presentation.** Sachets, each containing guar gum granules 5 grams. The fine pale cream granules are tasteless and readily water-miscible. Cartons of 100 sachets. **Product Licence Numbers.** PL0237/0023 & 0026. PA 3/6/1. Further information available from Rybar Laboratories Ltd., Amersham, Bucks, UK.

Rybar

HAVE YOU LOOKED DOWN A PENTAX FLEXIBLE FIBRESCOPE RECENTLY?



You will be surprised at the superb clear, sharp, bright image from the multicoated Pentax lenses and the lightweight compact control head helps you to manipulate the very manoeuvrable distal tip.

Positive air/water buttons, together with the offset biopsy channel, places you in total control.

Pentax scopes are compatible with most other manufacturers' equipment by use of simple adapters.

Serviced and repaired by factory trained technicians, backed up with Service Contracts and a full 12 months' 'All Risk' warranty.

When considering your next scope, you should have a look down a Pentax.

To arrange a demonstration of a Pentax fibreoptic, write or telephone, to the address below.

Then see for yourself!

PENTAX

LOOKING AHEAD

Pentax U.K. Limited,
Medical Division,
Pentax House,
South Hill Avenue,
South Harrow,
Middlesex, HA2 0LT.
Tel: 01-864 9477.

24-h-pH-Metry will become Routine in Gastroenterology

using the new GastrographH with the combined Ingold Electrode (no skin reference)

For the Practitioner:

No Computer or other ancillary equipment is necessary. The Gastrograph is its own Computer, pH-Meter and Printer – all combined in one. The printout is available in minutes.

For the Investigator:

The printout can be complemented by transferring the data to another PC. Either you can use your own statistics on the raw data – or we also supply statistics packages for a single patient, groups of 20 patients or groups of 200 patients, including graphics.



MIC AG, Medical Instruments Corporation, CH 4502 Solothurn, POB 706, Friedhofplatz 16,
Tel. 41-65-234355-56, Telex 931486 mic ch, FAX 41-65-221792

International Journals



Chirurgia del Piede Foot Surgery

Bi-monthly Review
Official Journal of the Italian, Belgian, Switzerland and Spanish Society for Foot Surgery
Yearly subscription **$ 80.00** including postage

Europa Medicophysica

Quarterly Review
Official Journal of the European Federation of Physical Medicine and Rehabilitation
Yearly subscription **$ 60.00** including postage

International Angiology

Quarterly Review
Official Journal of the International Union of Angiology
Yearly subscription **$ 60.00** including postage

International Journal of Sports Cardiology

Semi-yearly Review
Official Journal of the Italian Society of Sports Cardiology
Yearly subscription **$ 40.00** including postage

International Surgery

Quarterly Review
Official Journal of the International College of Surgeons
Yearly subscription **$ 60.00** including postage

The Journal of Cardiovascular Surgery

Bi-monthly Review
Official Journal of the International Society for Cardiovascular Surgery
Yearly subscription **$ 80.00** including postage

Journal of Neurosurgical Sciences

Quarterly Review
Official Organ on the Italian Society of Neurosurgery
Yearly subscription **$ 60.00** including postage

The Journal of Nuclear Medicine and Allied Sciences

Quarterly Review
Organ of the Italian Society for Nuclear Biology and Medicine
Yearly subscription **$ 60.00** including postage

The Journal of Sports Medicine and Physical Fitness

Quarterly Review
Yearly subscription **$ 60.00** including postage

Panminerva Medica

Quarterly Review
Official Journal of the Italian Medical Asscciation - Official Journal of Europa Medica
Yearly subscription **$ 60.00** including postage

Published by Minerva Medica

SCANDINAVIAN JOURNAL OF Gastroenterology

VOLUME 22, NO. 9, NOVEMBER 1987

CONTENTS

Abstracted in *Excerpta Medica*
Indexed in *Current Contents* and *Index Medicus* ISSN 0036-5521
Spanish edition distributed by Sanidad Ediciones, S.A.
Chinese edition distributed by The Shanghai Institute of Digestive Diseases

Annual subscription (ten issues per year) NOK 1,600,-/ USD 267.00

Publisher: Norwegian University Press (Universitetsforlaget/AS), P.O. Box 2959 Tøyen, Oslo 6, Norway.
U.S. office: Publications Expediting Inc., 200 Meacham Ave., Elmont, NY 11003, USA.